Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Atreca, Inc. (BCEL)

2.2   -0.29 (-11.65%) 08-18 07:05
Open: 2.47 Pre. Close: 2.49
High: 2.47 Low: 2.18
Volume: 136,926 Market Cap: 85(M)
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.47 - 2.49 2.49 - 2.5
Low: 2.15 - 2.17 2.17 - 2.18
Close: 2.18 - 2.2 2.2 - 2.22

Technical analysis

as of: 2022-08-17 4:21:42 PM
Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 2.85     One year: 3.26
Support: Support1: 1.87    Support2: 1.56
Resistance: Resistance1: 2.44    Resistance2: 2.79
Pivot: 2.3
Moving Average: MA(5): 2.49     MA(20): 2.23
MA(100): 2.14     MA(250): 3.27
MACD: MACD(12,26): 0.1     Signal(9): 0
Stochastic oscillator: %K(14,3): 65.1     %D(3): 79.2
RSI: RSI(14): 48.5
52-week: High: 7  Low: 1.5
Average Vol(K): 3-Month: 295 (K)  10-Days: 194 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ BCEL ] has closed above bottom band by 38.9%. Bollinger Bands are 17.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 17 Aug 2022
Atreca (BCEL) Drops in Light Trading for August 17 - Equities News

Tue, 16 Aug 2022
How Much Of Atreca, Inc. (NASDAQ:BCEL) Do Institutions Own? - Simply Wall St

Mon, 01 Aug 2022
Atreca, Inc. (BCEL) Stock Price Today, Quote & News - Seeking Alpha

Thu, 16 Jun 2022
Atreca names former Roche executive as new science chief (NASDAQ:BCEL) - Seeking Alpha

Wed, 01 Jun 2022
Atreca announces corporate reorganization, to cut workforce by more than 25% - Seeking Alpha

Wed, 11 May 2022
Atreca Reports First Quarter 2022 Financial Results and Recent Corporate Developments - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 32 (M)
Shares Float 25 (M)
% Held by Insiders 3.2 (%)
% Held by Institutions 61.3 (%)
Shares Short 2,910 (K)
Shares Short P.Month 4,020 (K)

Stock Financials

EPS -2.91
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.56
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -28.9
Return on Equity (ttm) -60.4
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -3.28
Qtrly Earnings Growth 0
Operating Cash Flow -69 (M)
Levered Free Cash Flow -71 (M)

Stock Valuations

PE Ratio -0.76
PEG Ratio 0
Price to Book value 0.61
Price to Sales 0
Price to Cash Flow -1.02

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.